Start free

Attovia Therapeutics, Inc. (ATTO) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Oct 8, 2026.

Filings shown
14
Open-market buys
9
Open-market sells
46
Buys, 10b5-1 box not checked
9 of 9

Counts cover the 14 most recent Form 4 filings Tradune holds for ATTO (filed Aug 6 – Oct 8, 2026). SEC EDGAR Form 4 filings for ATTO last checked Nov 22, 2026, 09:00 UTC; the latest ATTO filing Tradune holds was filed Oct 8, 2026. This is not guaranteed to be the complete record — see ATTO's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 4 filings Tradune holds for ATTO filed Aug 28 – Oct 8, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

46 open-market sales by Rule 10b5-1 checkbox

On filings with the 10b5-1 box checked
0 sales· 0 sh
checkbox disclosed
On filings with the box not checked
46 sales· 211,614 sh
not proof that no plan exists
Not comparable
0 sales· 0 sh
filed before Apr 1, 2023, or no checkbox value in the filing data

Counts are Form 4 lines as filed. The checkbox is one per filing, so every sale on a filing with the box checked is counted there even if only some of its transactions were under a plan; it records what the filer disclosed, and the three categories are not a judgement about why a sale was made.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold
Goldman Sachs Group IncInsider 2 23 585,000 105,807
Colin WalshDirector 2 23 585,000 105,807

Dollar value: value undisclosed — at least one Form 4 in this window has no complete disclosed value, so totals are not shown.

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at ATTO

Insiders reported 9 open-market purchases of ATTO between Aug 6, 2026 and Oct 8, 2026, across 6 distinct buyers. The most recent purchase was reported by Frazier Life Sciences Xi, L.P. (10% owner) on Aug 6, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Steven Chan amended Chief Financial Officer · filed Oct 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 140,000 — — — Aug 4, 2026
Tao Fu amended President and CEO · filed Oct 8, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 538,300 — — — Aug 4, 2026
Colin Walsh amended Director · filed Aug 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 1,957,134 — 2,042,134 (indirect) +2,303% Aug 6, 2026
Conversion of derivative 478,498 — 2,520,632 (indirect) +23% Aug 6, 2026
Open-market purchase 10b5-1 box not checked 500,000 $17.00 3,020,632 (indirect) +20% Aug 6, 2026
Conversion of derivative Series B Preferred Stock 18,181,830 — — — Aug 6, 2026
Conversion of derivative Series C Preferred Stock 4,445,275 — — — Aug 6, 2026
Open-market sale 10b5-1 box not checked 200 $22.05 82,033 (indirect) −0.2% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,556 $22.06 80,477 (indirect) −1.9% Aug 5, 2026
Open-market sale 10b5-1 box not checked 3,402 $22.02 77,075 (indirect) −4.2% Aug 5, 2026
Open-market sale 10b5-1 box not checked 200 $22.10 76,875 (indirect) −0.3% Aug 5, 2026
Open-market sale 10b5-1 box not checked 480 $21.55 76,395 (indirect) −0.6% Aug 5, 2026
Open-market sale 10b5-1 box not checked 100 $22.11 76,295 (indirect) −0.1% Aug 5, 2026
Open-market sale 10b5-1 box not checked 753 $21.97 75,542 (indirect) −1.0% Aug 5, 2026
Open-market sale 10b5-1 box not checked 672 $22.02 74,870 (indirect) −0.9% Aug 5, 2026
Open-market sale 10b5-1 box not checked 400 $22.02 67,500 (indirect) −0.6% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,180 $21.84 66,320 (indirect) −1.7% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,040 $22.05 65,280 (indirect) −1.6% Aug 5, 2026
Open-market sale 10b5-1 box not checked 300 $20.84 64,980 (indirect) −0.5% Aug 5, 2026
Open-market sale 10b5-1 box not checked 443 $21.78 64,537 (indirect) −0.7% Aug 5, 2026
Open-market sale 10b5-1 box not checked 200 $22.05 64,337 (indirect) −0.3% Aug 5, 2026
Open-market sale 10b5-1 box not checked 700 $22.07 63,637 (indirect) −1.1% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,163 $22.19 62,474 (indirect) −1.8% Aug 5, 2026
Open-market sale 10b5-1 box not checked 100 $21.99 62,374 (indirect) −0.2% Aug 5, 2026
Open-market sale 10b5-1 box not checked 6,763 $21.61 55,611 (indirect) −11% Aug 5, 2026
Open-market sale 10b5-1 box not checked 76,418 $21.04 0 (indirect) −100% Aug 5, 2026
Open-market sale 10b5-1 box not checked 6,970 $22.03 67,900 (indirect) −9.3% Aug 5, 2026
Open-market purchase 10b5-1 box not checked 85,000 $21.00 85,000 (indirect) — Aug 5, 2026
Open-market sale 10b5-1 box not checked 988 $22.03 84,012 (indirect) −1.2% Aug 5, 2026
Open-market sale 10b5-1 box not checked 447 $21.87 83,565 (indirect) −0.5% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,332 $22.03 82,233 (indirect) −1.6% Aug 5, 2026
Derivative purchase Equity Swap 2,872 $21.22 — — Aug 5, 2026
Derivative purchase Equity Swap 28,717 $21.22 — — Aug 5, 2026
Derivative purchase Equity Swap 11,488 $21.22 — — Aug 5, 2026
Derivative purchase Equity Swap 45,588 $21.27 — — Aug 5, 2026
Derivative purchase Equity Swap 11,398 $21.27 — — Aug 5, 2026
Derivative purchase Equity Swap 5,744 $21.22 — — Aug 5, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Goldman Sachs Group Inc amended Insider · filed Aug 28, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 1,957,134 — 2,042,134 (indirect) +2,303% Aug 6, 2026
Open-market purchase 10b5-1 box not checked 500,000 $17.00 3,020,632 (indirect) +20% Aug 6, 2026
Conversion of derivative Series B Preferred Stock 18,181,830 — — — Aug 6, 2026
Conversion of derivative Series C Preferred Stock 4,445,275 — — — Aug 6, 2026
Conversion of derivative 478,498 — 2,520,632 (indirect) +23% Aug 6, 2026
Open-market purchase 10b5-1 box not checked 85,000 $21.00 85,000 (indirect) — Aug 5, 2026
Open-market sale 10b5-1 box not checked 988 $22.03 84,012 (indirect) −1.2% Aug 5, 2026
Open-market sale 10b5-1 box not checked 447 $21.87 83,565 (indirect) −0.5% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,332 $22.03 82,233 (indirect) −1.6% Aug 5, 2026
Open-market sale 10b5-1 box not checked 200 $22.05 82,033 (indirect) −0.2% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,556 $22.06 80,477 (indirect) −1.9% Aug 5, 2026
Open-market sale 10b5-1 box not checked 3,402 $22.02 77,075 (indirect) −4.2% Aug 5, 2026
Open-market sale 10b5-1 box not checked 200 $22.10 76,875 (indirect) −0.3% Aug 5, 2026
Open-market sale 10b5-1 box not checked 480 $21.55 76,395 (indirect) −0.6% Aug 5, 2026
Open-market sale 10b5-1 box not checked 100 $22.11 76,295 (indirect) −0.1% Aug 5, 2026
Open-market sale 10b5-1 box not checked 753 $21.97 75,542 (indirect) −1.0% Aug 5, 2026
Open-market sale 10b5-1 box not checked 672 $22.02 74,870 (indirect) −0.9% Aug 5, 2026
Open-market sale 10b5-1 box not checked 6,970 $22.03 67,900 (indirect) −9.3% Aug 5, 2026
Open-market sale 10b5-1 box not checked 400 $22.02 67,500 (indirect) −0.6% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,180 $21.84 66,320 (indirect) −1.7% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,040 $22.05 65,280 (indirect) −1.6% Aug 5, 2026
Open-market sale 10b5-1 box not checked 300 $20.84 64,980 (indirect) −0.5% Aug 5, 2026
Open-market sale 10b5-1 box not checked 443 $21.78 64,537 (indirect) −0.7% Aug 5, 2026
Open-market sale 10b5-1 box not checked 200 $22.05 64,337 (indirect) −0.3% Aug 5, 2026
Open-market sale 10b5-1 box not checked 700 $22.07 63,637 (indirect) −1.1% Aug 5, 2026
Open-market sale 10b5-1 box not checked 1,163 $22.19 62,474 (indirect) −1.8% Aug 5, 2026
Open-market sale 10b5-1 box not checked 100 $21.99 62,374 (indirect) −0.2% Aug 5, 2026
Open-market sale 10b5-1 box not checked 6,763 $21.61 55,611 (indirect) −11% Aug 5, 2026
Open-market sale 10b5-1 box not checked 76,418 $21.04 0 (indirect) −100% Aug 5, 2026
Derivative purchase Equity Swap 2,872 $21.22 — — Aug 5, 2026
Derivative purchase Equity Swap 28,717 $21.22 — — Aug 5, 2026
Derivative purchase Equity Swap 11,488 $21.22 — — Aug 5, 2026
Derivative purchase Equity Swap 45,588 $21.27 — — Aug 5, 2026
Derivative purchase Equity Swap 11,398 $21.27 — — Aug 5, 2026
Derivative purchase Equity Swap 5,744 $21.22 — — Aug 5, 2026
Deep Track Biotechnology Master Fund, Ltd. 10% owner · filed Aug 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 1,957,138 — 1,957,138 — Aug 6, 2026
Conversion of derivative Series C Redeemable Convertible Preferred Stock 18,181,818 — — — Aug 6, 2026
venBio Global Strategic Fund IV, L.P. 10% owner · filed Aug 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 382,352 $17.00 4,181,367 +10% Aug 6, 2026
Conversion of derivative Series A Preferred Stock 21,477,273 — — — Aug 6, 2026
Conversion of derivative Series B Preferred Stock 7,636,362 — — — Aug 6, 2026
Conversion of derivative Series C Preferred Stock 6,179,219 — — — Aug 6, 2026
Conversion of derivative 2,311,870 — 2,311,870 — Aug 6, 2026
Conversion of derivative 821,998 — 3,133,868 +36% Aug 6, 2026
Conversion of derivative 665,147 — 3,799,015 +21% Aug 6, 2026
Sanofi 10% owner · filed Aug 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 782,855 — 782,855 (indirect) — Aug 6, 2026
Open-market purchase 10b5-1 box not checked 300,000 $17.00 1,082,855 (indirect) +38% Aug 6, 2026
Conversion of derivative Series C Preferred Stock 782,855 — — — Aug 6, 2026
Redmile Group, LLC 10% owner · filed Aug 7, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 782,854 — 782,854 (indirect) — Aug 6, 2026
Open-market purchase 10b5-1 box not checked 200,000 $17.00 982,854 +26% Aug 6, 2026
Open-market purchase 10b5-1 box not checked 400,000 $17.00 1,182,854 (indirect) +51% Aug 6, 2026
Conversion of derivative Series B Preferred Stock 782,854 — — — Aug 6, 2026
Frazier Life Sciences Xi, L.P. 10% owner · filed Aug 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative Series B Preferred Stock 11,054,544 — — — Aug 6, 2026
Conversion of derivative Series A-1 Preferred Stock 16,250,000 — — — Aug 6, 2026
Conversion of derivative Series C Preferred Stock 8,930,685 — — — Aug 6, 2026
Open-market purchase 10b5-1 box not checked 588,235 $17.00 6,154,213 +11% Aug 6, 2026
Conversion of derivative 961,322 — 5,565,978 +21% Aug 6, 2026
Conversion of derivative 1,189,940 — 4,604,656 +35% Aug 6, 2026
Conversion of derivative 1,590,175 — 3,414,716 +87% Aug 6, 2026
Conversion of derivative 1,749,192 — 1,824,541 +2,321% Aug 6, 2026
Conversion of derivative Series A-2 Preferred Stock 14,772,727 — — — Aug 6, 2026
Hubert Chen Chief Medical Officer · filed Aug 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 140,000 — — — Aug 4, 2026
Petter Veiby Chief Scientific Officer · filed Aug 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 140,000 — — — Aug 4, 2026
Zaneta Odrowaz Chief Business Officer · filed Aug 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 140,000 — — — Aug 4, 2026
Mitchell Gold Director · filed Aug 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 27,000 — — — Aug 4, 2026
Angie You Director · filed Aug 6, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 27,000 — — — Aug 4, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to ATTO's (Oct 8, 2026).

Frequently asked about ATTO insider activity

How many insiders bought ATTO stock in these Form 4 filings?

6 distinct insiders at Attovia Therapeutics, Inc. reported 9 open-market purchases (Form 4 code P) of ATTO shares between Aug 6, 2026 and Oct 8, 2026, the most recent filed by Frazier Life Sciences Xi, L.P. (10% owner) on Aug 6, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for ATTO?

The most recent Form 4 on this page was filed by Tao Fu (President and CEO) on Oct 8, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market ATTO insider purchase shown?

The largest open-market purchase among the filings shown was 588,235 ATTO shares at $17.00 (about $9,999,995) by Frazier Life Sciences Xi, L.P. (10% owner) on Aug 6, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent ATTO insider purchases have the Form 4 10b5-1 box checked?

No. All 9 ATTO open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Frazier Life Sciences Xi, L.P. (10% owner) on Aug 6, 2026, 588,235 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for ATTO — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.